Tuoxin Pharmaceutical Group (301089.SZ) has forecasted a pre-tax loss, anticipating a net loss of 15-21 million yuan for the year 2024, turning from profit to loss.

Tuoxin Pharmaceutical Group (301089.SZ) released the 2024 annual performance forecast, and the company expects a net loss attributable to shareholders of the listed company in 2024 of 15-21 million yuan, turning from profit to loss; deducting non-recurring gains and losses, the net loss is expected to be 22.6-28.6 million yuan, also turning from profit to loss.